Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01903083 · ClinicalTrials.gov registry record · Phase 1

Chemoimmunotherapy and Radiation in Pancreatic Cancer

A Phase 1 study of Locally Advanced Malignant Neoplasm, sponsored by Providence Health & Services.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT01903083: Completed Phase 1 study of Locally Advanced Malignant Neoplasm, sponsored by Providence Health & Services.

NCT01903083 is a Phase 1 study of Locally Advanced Malignant Neoplasm that has completed, run by Providence Health & Services. The registered enrollment target is 10 participants, below the 123-participant average among 11 other Locally Advanced Malignant Neoplasm trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01903083, a Phase 1 study of Locally Advanced Malignant Neoplasm, has completed, sponsored by Providence Health & Services.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.

Primary Outcome

Patients will return be seen in the clinic 8 times over the first 50 days for an evaluation of adverse events and toxicities before being evaluated for surgery. Patients who are not candidates for surgery will be seen in clinic 10 more times over the next 85 days for safety evaluations, and patients who have surgery will be seen 10 times over the 85 days following recovery from surgery for safety evaluations.

Interventions

  • DRUG Gemcitabine
  • RADIATION Radiation
  • DRUG Tadalafil
  • PROCEDURE Pancreaticoduodenectomy

Study Locations (1)

Oregon

  • Portland Providence Medical Center - Portland

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2013-07
Est. Completion 2017-12
Phase Phase 1
Providence Health & Services

69 total trials

What the finished NCT01903083 record still lists

NCT01903083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 123-participant average among 11 other Locally Advanced Malignant Neoplasm trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Locally Advanced Malignant Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Gemcitabine is the first listed.

NCT01903083 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT01903083 about?

NCT01903083 is a clinical study titled "Chemoimmunotherapy and Radiation in Pancreatic Cancer". The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.

What is the current status of trial NCT01903083?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2013-07. Estimated completion is 2017-12.

What conditions does trial NCT01903083 study?

This clinical trial studies the following conditions: Locally Advanced Malignant Neoplasm.

What interventions are being tested in trial NCT01903083?

The interventions under investigation include: Gemcitabine (DRUG), Radiation (RADIATION), Tadalafil (DRUG), Pancreaticoduodenectomy (PROCEDURE).

Who is sponsoring clinical trial NCT01903083?

This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01903083 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Locally Advanced Malignant Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01903083's enrollment target sits among peer trials

10 11th of 11 the lowest of 11 other Locally Advanced Malignant Neoplasm trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Locally Advanced Malignant Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01903083, the US trial registry maintained by the National Library of Medicine. NCT01903083 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.